eye drops delay, will prevent, myopia

Published Date: 16 Feb 2023

Researchers have found that dilating eye drops that children use daily can delay the onset of myopia.

Read Full News

Latest News

Common Epilepsy Drug Tied to Increased Glaucoma Risk

Use of topiramate is linked to a higher risk for glaucoma than valproate or lamotrigine, especially in women and patients with epilepsy, new research shows.

Worsening Heart-Kidney-Metabolic Health May Threaten Vision

People with worsening cardiovascular-kidney-metabolic syndrome may face an increased risk for developing age-related macular degeneration.

Beyond Skin Deep: Biologics May Benefit Eyes in Psoriasis

In patients with psoriasis, biologics may reduce ocular surface and corneal inflammation — especially dry eye, conjunctivitis, and keratitis — but they do not consistently alleviate retinal disease.

Study Maps Extensive Disease Links Beyond Childhood Eczema

Using millions of NHS records, researchers mapped extensive links between childhood eczema and later inflammatory and eye diseases.

Neoadjuvant Therapy Use Rising Sharply in Cancer Care

The second annual NCDB report reveals a major shift toward preoperative systemic therapy in solid tumors, offering new opportunities for de-escalation, although careful patient selection is needed.

New Rx Option for Neuromyelitis Optica Spectrum Disorder?

Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Todays Updates

Immunotherapy Remains Little Used in Head and Neck Cancer

Immune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.

EVP Beats Cisplatin for Resectable MIBC

As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Latest News

Use of topiramate is linked to a higher risk for glaucoma than valproate or lamotrigine, especially in women and patients with epilepsy, new research shows.

People with worsening cardiovascular-kidney-metabolic syndrome may face an increased risk for developing age-related macular degeneration.

In patients with psoriasis, biologics may reduce ocular surface and corneal inflammation — especially dry eye, conjunctivitis, and keratitis — but they do not consistently alleviate retinal disease.

Using millions of NHS records, researchers mapped extensive links between childhood eczema and later inflammatory and eye diseases.

The second annual NCDB report reveals a major shift toward preoperative systemic therapy in solid tumors, offering new opportunities for de-escalation, although careful patient selection is needed.

Phase 3 trial results suggest daratumumab, which is approved for multiple myeloma, may also be effective at reducing relapse risk in neuromyelitis optica spectrum disorder.

News All Time

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Q3 2025 Recap: Ophthalmology News and Updates Ryan Livingston

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

Psoriasis Associated with Risk of Age-Related Macular Degeneration Ryan Livingston

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

Correlation Between Diabetes and Risk of Uveitis Confirmed in Recent Study Ryan Livingston

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

Dyslipidemia May Delay Macular Hole Closure After Surgery Ryan Livingston

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

FDA Approves Incision-Free Topical Therapy Epioxa for Keratoconus Ryan Livingston

This approval represents an alternative method for approaching this undertreated disease, shortening recovery while minimizing invasiveness.

FDA Approves Adalimumab-aaty (Yuflyma) Pediatric Indications in Hidradenitis Suppurativa, Uveitis Abigail Brooks, MA

The FDA approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of adolescent HS and pediatric UV.

Brolucizumab Outperforms Aflibercept in DME Regardless of Prior Treatment

Brolucizumab Outperforms Aflibercept in DME Regardless of Prior Treatment

GLP-1 RAs May Influence Development of Nonexudative AMD in Patients With Obesity Ryan Livingston

Although no direct correlation can be drawn, these findings suggest a possible ocular benefit from GLP-1 RAs compared to other weight loss drugs.

Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 for Wet AMD

Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 for Wet AMD

Temporal artery ultrasound in the real-time diagnosis of stroke of the eye

For most of us, the phrase "stroke of the eye" sounds like a metaphor. But for UK HealthCare's Jagannadha "Jay" Avasarala, M.D., Ph.D., it's a literal and urgent diagnosis—one that could mean the difference between sight ...

Recommended News For You

Asymptomatic or Minimally Symptomatic Myelofibrosis

novel approach to test the toxicity of cancer drugs.

A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.

AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence

High numbers of rural patients cross state lines for cancer care

Prostate cancer screening program beneficial in top decile of polygenic risk score

Clinical trial results show low-intensity therapy can achieve positive outcomes for certain pediatric leukemia subtypes

Recommended Articles For You

Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies 

The Science Behind Thrombolytic Drugs and Their Benefits  

Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources 

Uncovering the Secrets of CA19-9: A Blood Test for Cancer Diagnosis 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can Prior Authorization Be Better With Artificial Intelligence?

2.

One-third of childhood cancer survivors experience significant fear that it could come back, study reveals

3.

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

4.

No increased risk of childhood cancer near UK nuclear sites, study finds

5.

A promising medication could slow brain tumors in children.

1.

Advancing Cancer Care: Insights into Oncology Trials, Immunotherapy, and CAR-T Innovations

2.

How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies

3.

Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging

4.

Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections

5.

Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

2.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

3.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot